Separately, ValuEngine raised shares of Atossa Genetics from a sell rating to a hold rating in a report on Wednesday, May 2nd.
ATOS stock opened at $3.73 on Monday. Atossa Genetics has a fifty-two week low of $3.86 and a fifty-two week high of $3.86.
Atossa Genetics (NASDAQ:ATOS) last posted its quarterly earnings data on Monday, May 14th. The company reported ($0.71) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.15. analysts expect that Atossa Genetics will post -4.68 EPS for the current fiscal year.
Atossa Genetics Company Profile
Atossa Genetics Inc a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions.
Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.